NAXUS® is an arabinoxylan concentrate from wheat. NAXUS has been evaluated in a number of clinical studies for its effects on glycemic control and benefits from a specific EFSA approved health claim for glycemic control. NAXUS has also shown profound effects on the human microbiota with knock-on effects on the improvement of several metabolic processes.
Recent preclinical results obtained by Ghent University and Universite Catholique de Louvain (UCL) have been accepted in two peer-reviewed journals. The paper published by Ghent University in the Journal of Agricultural and Food Chemistry further confirms the highly selective effects of NAXUS on the gut microbiota based on a set of gut model studies. The manuscript published by UCL in British Journal of Nutrition describes a novel downstream metabolic pathway which further helps to explain the positive effects of NAXUS on metabolic control, in a well-established animal model for obesity.
To further strengthen its NAXUS research program, BioActor has signed a Collaboration Agreement with Ghent University to study the effects of NAXUS on the gut microbiota and the downstream effects on gut barrier function. BioActor has already obtained strong preclinical data indicating that NAXUS affects markers for barrier function. BioActor is currently conducting a large clinical study to validate these effects in human volunteers. In this context, BioActor will provide Ghent University with gut biopsies, intestinal and fecal samples from this clinical trial to characterize the microbiota and correlate changes with downstream effects on gut barrier function.